The Technical Analyst
Cassava Sciences Inc [SAVA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cassava Sciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.24% $20.55
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 888.28 mill |
| EPS: | -2.32 |
| P/E: | -8.86 |
| Earnings Date: | Apr 29, 2024 |
| SharesOutstanding: | 43.23 mill |
| Avg Daily Volume: | 0.736 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.86 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.51x |
| Company: PE -8.86 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.89 (-85.94%) $-17.66 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 19.47 - 21.63 ( +/- 5.24%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-18 | Kupiec James William | Buy | 1 500 | Common Stock |
| 2024-01-03 | Kupiec James William | Buy | 1 000 | Common Stock Warrant |
| 2024-04-18 | Kupiec James William | Sell | 1 000 | Common Stock Warrant |
| 2024-04-17 | Schoen Eric | Buy | 1 500 | Common Stock |
| 2024-01-03 | Schoen Eric | Buy | 7 920 | Common Stock Warrant |
| INSIDER POWER |
|---|
| 79.75 |
| Last 90 transactions |
| Buy: 1 745 541 | Sell: 549 962 |
Forecast:
16:00 - $20.52
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $20.52
Forecast 2: 16:00 - $20.52
Forecast 3: 16:00 - $20.52
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $20.55 (0.24% ) |
| Volume | 0.498 mill |
| Avg. Vol. | 0.736 mill |
| % of Avg. Vol | 67.61 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SAVA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $25.39 | N/A | Active |
|---|
SAVA
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Latest Press Releases
2024-04-15 09:20:00 - Press Release
Redemption Date Announced For Warrants
Austin, texas, april 15, 2024 (globe newswire) -- cassava sciences, inc. (nasdaq: sava) (“cassava sciences” or the "company") today announced that monday, may 6, 2024 is the last and final day to exercise the warrants that were previously distributed to its shareholders on january 3, 2024 (the “warrants”). holders who exercise their warrants will receive 1.5 shares of cassava sciences' common stock per warrant, for an effective price of approximately $22.00 per share.
2024-04-01 23:00:00 - Press Release
Final Deadline Today: The Schall Law Firm Encourages Investors In Cassava Sciences, Inc. With Losses Of $100,000 To Contact The Firm
Los angeles, ca / accesswire / april 1, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against cassava sciences, inc.. ("cassava" or "the company") (nasdaq:sava) for violations of 10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission.
2024-04-01 06:00:00 - Press Release
Final Deadline Tuesday: The Schall Law Firm Encourages Investors In Cassava Sciences, Inc. With Losses To Contact The Firm
Los angeles, ca / accesswire / april 1, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against cassava sciences, inc.. ("cassava" or "the company") (nasdaq: sava) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission.
2024-03-31 07:00:00 - Press Release
April 2 Final Deadline: The Schall Law Firm Encourages Investors In Cassava Sciences, Inc. With Losses Of $100,000 To Contact The Firm
Los angeles, ca / accesswire / march 31, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against cassava sciences, inc.. ("cassava" or "the company") (nasdaq: sava) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission.
2024-03-30 07:00:00 - Press Release
Final Deadline Tuesday: The Schall Law Firm Encourages Investors In Cassava Sciences, Inc. With Losses Of $100,000 To Contact The Firm
Los angeles, ca / accesswire / march 30, 2024 / the schall law firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against cassava sciences, inc.. ("cassava" or "the company") (nasdaq: sava) for violations of §§10(b) and 20(a) of the securities exchange act of 1934 and rule 10b-5 promulgated thereunder by the u.s. securities and exchange commission.
Latest News
2024-03-04 09:15:00 - GlobeNewsWire
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
AUSTIN, Texas, March 04, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced plans to present a virtual oral presentation at the International Conference on Alzheimer's and Parkison's Disease (AD/PD 2024) taking place in Lisbon, Portugal from March 5-9, 2024.
2024-02-21 16:50:00 - InvestorPlace
Exit Now! 3 Biotech Stocks to Sell in February 2024
The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges.
2024-02-06 10:16:11 - MarketBeat
3 small-cap biotechs with potential breakthroughs in 2024
There's a reason that many biotech investors prefer to stick with large-cap stocks. Investing in small-cap biotech stocks is not for risk-averse investors.
2024-02-03 10:15:00 - The Motley Fool
Is There Any Hope for Cassava Sciences Stock?
Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to produce favorable data.
2024-01-25 17:29:17 - InvestorPlace
3 Biotech Stocks to Sell in January Before They Crash and Burn
The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies' performance relies heavily on drug approvals.
2024-01-12 14:21:55 - InvestorPlace
Portfolio Protection: 7 Risky Stocks to Drop Right Now
With investors moving back towards a “risk-on” stance in recent months, you may think that risky stocks could lead to outsized rewards this year. Yet while more favorable economic and market conditions could extend the current bull market (which started in October) well into 2024, an improving macro picture may not be enough for stocks that have large company-specific risks.
2024-01-05 11:46:28 - InvestorPlace
New SAVAW Warrants Are Trading After Cassava Sciences' Distribution
In the biotechnology sector, Cassava Sciences (NADSAQ: SAVA ) remains one of the top clinical-stage companies that investors are watching. Over the past one year, SAVA stock is down by less than 20% but up nearly 9% for the past six months.
2023-12-15 18:06:45 - The Motley Fool
Why Cassava Sciences Stock Zoomed 21% Higher This Week
The biotech has declared a fresh dividend. The payout is rather atypical -- it's in the form of common stock warrants.
2023-12-12 14:02:18 - InvestorPlace
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
Shares of pharmaceutical specialist Cassava Sciences (NASDAQ: SAVA ) soared earlier Tuesday before giving up most of the gains. Nevertheless, investor enthusiasm spiked over management's decision to issue a warrant distribution to support the ongoing Phase 3 clinical development of oral simulfilam, a promising therapeutic for patients of Alzheimer's disease.
2023-12-08 19:31:08 - The Motley Fool
Why Cassava Sciences Stock Soared Today
The biotech significantly modified its board of directors. Two of those incoming directors have extensive experience in the healthcare field; the other comes from the security sphere.